Global Microbiome Therapeutics Market Analysis Report 2023: A $1.46 Billion Market by 2027 Featuring Major Players - Assembly Bio, Finch Therapeutics, Second Genome, Evelo Bio, Ysopia Bio
DUBLIN, Feb. 9, 2023
DUBLIN, Feb. 9, 2023 /PRNewswire/ -- The "Microbiome Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering.
The global Microbiome Therapeutics market is projected to reach a value of $1,465.3 million by 2027, from $164.8 million in 2022, growing at a CAGR of 54.8%
Microbiome Therapeutics: Global Markets Report provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2027.
The microbiome has become a buzz word and attracted millions of dollars in federal grants, awards and funding from venture capitalists. Technological advancements in next-generation sequencing and data analytics clubbed with modern approaches of systems biology and genetic engineering have greatly expanded the knowledge of commensal microbial populations and interactions with human hosts.
The Human Microbiome Project (HMP), MetaHIT and other independent efforts fueling the exploration of microbiome and its association with human health have led to a research explosion in this area in the last decade. Myriad studies abound showing how the microbiome mediate many physiological processes (metabolism, nutrition, immunity, etc.).
Many clinical studies show alterations in microbial populations or microbial dysbiosis can lead to disease. Restoration of the microbiome addresses many unmet medical needs. Diseases that still do not have definitive cures or with available treatments that are either not satisfactory or are cost-prohibitive, are actively targeted by microbiome therapeutics.
There are many active players in the field of microbiome therapeutics, ranging from discovery and clinical-stage to late-stage companies that are exploiting different approaches to modulate the microbiome. Fecal microbial transplants (FMTs) have been in practice for some time and the use of live biotherapeutic products (LBPs) in the form of single strains or microbial consortia is a popular strategy with targeted mechanisms and controlled production processes. The development of small molecule drugs (postbiotics) and the use of phages are being actively explored.
Currently, no microbiome therapeutic is approved in the U.S. or in any other market. There are some candidates in Phase 3 trials (Seres Therapeutics SER109 and Rebiotix's RBX2660) that are being evaluated for the treatment of recurrent Clostridium difficile infection. Despite an expansive patent portfolio and a large number of clinical trials in the field of microbiome therapeutics, the market is facing some challenges.
The absence of any regulatory framework brings uncertainty for many developers in this novel market. The complexity of the human microbiome and variations among different individuals add to difficulties in the design of clinical trials. Additional hurdles are expected during scaling.
For the microbiome therapeutics market to grow, a strong collaborative effort is needed from all stakeholders, including the regulatory agencies. Statistically-relevant results and proof-of-concept studies driven by technological advancements in biomarkers, functional assays and computational biology are required that will eventually pave the way for product approvals.
The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting growth of this market in the global context.
The new report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and leading pipeline candidates. This chapter covers influential mergers and acquisitions and other collaborations or partnerships that happened during the evaluation period of this report.
Strengths, weaknesses, threats, and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.
The markets for prebiotics and probiotics labeled as nutritional or dietary supplements are excluded from this report. Prebiotics and probiotics are included when used in the context of microbiome therapy.
- Analyses of the global market trends, with historic market revenue (sales data) for 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
- Discussion of the industry growth driving factors and major technology challenges and issues affecting the market for microbiome therapeutics as a basis for projecting demand over the next few years (2022-2027)
- Estimation of the actual market size and revenue forecast for global microbiome therapeutics market in USD million terms, and corresponding market share analysis by technology type, application, and region
- Highlights of this innovation driven market covering current trends in genome sequencing industry, disease areas of application, clinical trials and their stages, and recent breakthrough innovations etc.
- Assessment of the recent industry structure for microbiome therapeutics, ongoing research (R&D) activities, analysis of competitive environment, and the COVID-19 impact on the marketplace
- Review of the patents and patent applications on microbiome therapeutics, and related scientific publications during the analysis period
- Competitive landscape of this market featuring leading biopharmaceutical companies, their product portfolios, financial updates, and market share analysis based on recent segmental revenues
- Profile description of the major market participants, including Assembly Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences, Ysopia Bioscience
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
3.2 the Human Microbiome
3.2.1 Different Microbiomes in Humans
3.2.2 Microbiome, Human Health and Disease
3.2.3 Technologies Aiding Microbiome Research
3.2.4 Microbiome Research Projects
3.3 Microbiome Therapeutics
3.3.1 Strategies for the Development of Microbiome Therapeutics
3.3.2 Microbiome Therapeutics Disease Areas
3.3.3 Regulatory Landscape for Microbiome Therapeutics
Chapter 4 Market Breakdown by Type of Therapeutic
4.2 Market Overview
4.2.1 Market Revenue
4.2.2 Market Shares
4.3 Additive Microbiome Therapeutics
4.3.1 Fecal Microbiota Transplants (Fmts)
4.3.2 Live Biotherapeutic Products (Lbps)
4.3.3 Market Overview
4.3.4 Market Revenue
4.3.5 Market Shares
4.4 Modulatory Microbiome Therapeutics
4.4.1 Mechanism of Action
4.4.2 Current Status
4.4.3 Market Overview
4.4.4 Market Revenue
4.4.5 Market Shares
4.5 Subtractive Microbiome Therapeutics
Chapter 5 Market Breakdown by Application
5.1.1 Market Revenue
5.1.2 Market Shares
5.2.1 Clostridium Difficile Infection (Cdi)
5.2.2 Urinary Tract Infection (Uti)
5.2.4 Market Overview
5.2.5 Market Revenue
5.3 Gastrointestinal (Git) Diseases
5.4 Metabolic Diseases
5.6 Gut-Brain Axis Diseases
5.7 Other Diseases
Chapter 6 Industry Structure
6.1 Investment in Microbiome Therapeutics
6.1.1 Public Funding Initiatives
6.1.2 Private Funding Initiatives
6.2 Collaborations and Partnerships
6.3 Licensing and Manufacturing Agreements
6.4 Mergers and Acquisitions
6.5 Leading Market Players in the Market for Microbiome Therapeutics
6.5.1 Leading Market Players in Market for Additive Microbiome Therapeutics
6.5.2 Leading Market Players in the Market for Modulatory Microbiome Therapeutics
6.5.3 Leading Market Players in the Market for Subtractive Microbiome Therapeutics
6.6 Research Select Insights from Industry Leaders
Chapter 7 Patent Analysis
7.1 Patent Analysis
7.1.1 Patents by Year
7.1.2 Patents by Type
7.1.3 Patents by Type of Disease
7.1.4 Patents by Company
7.1.5 Patents by Country
7.1.6 Patents by Assignee
Chapter 8 Clinical Trials
8.1 Clinical Trials by Disease Category
8.1.1 Distribution Shares of Clinical Trials
8.2 Clinical Trials by Type of Therapeutic
8.2.1 Distribution Shares of Clinical Trials by Type of Therapeutic
8.3 Clinical Trials by Company
8.3.1 Distribution Shares of Clinical Trials by Company
8.3.2 Microbiome Therapeutics in Discovery and Preclinical Development
8.3.3 Microbiome Therapeutics in Phase 3 Clinical Trials
Chapter 9 Analysis of Market Opportunities
9.1 SWOT Analysis
9.1.1 Strengths of Market for Microbiome Therapeutics
9.1.2 Challenges in the Market for Microbiome Therapeutics
9.1.3 Opportunities in the Market for Microbiome Therapeutics
9.1.4 Threats to the Market for Microbiome Therapeutics
Chapter 10 Company Profiles
- 4D Pharma
- Ao Biome LLC
- Assembly Biosciences Inc.
- Armata Pharmaceuticals
- Azitra Inc.
- Chain Biotechnology Ltd.
- Eligo Bioscience Sas
- Enterome Sa
- Evelo Biosciences
- Finch Therapeutics Group Inc.
- Intralytix Inc.
- Maat Pharma
- Osel Inc.
- Pylum Biosciences Inc.
- Quorum Innovations LLC
- Rebiotix Inc. (A Ferring Company)
- Second Genome
- Senda Biosciences Inc.
- Seres Therapeutics Inc.
- Sfa Therapeutics Inc.
- Theriva Biologics Inc.
- Vedanta Biosciences Inc.
- Ysopia Bioscience Inc.
For more information about this report visit https://www.researchandmarkets.com/r/nkzqru
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-microbiome-therapeutics-market-analysis-report-2023-a-1-46-billion-market-by-2027-featuring-major-players---assembly-bio-finch-therapeutics-second-genome-evelo-bio-ysopia-bio-301743160.html
SOURCE Research and Markets
Everything Now: eating disorder recovery is treated with sensitivity and nuance in Netflix comedy drama
The series should be praised for recognising that it’s not just white, middle-class girls who experience eating disorders.
Netflix couldn’t have chosen a more resonant title than Everything Now for their new comedy drama series. When I came out of a residential clinic in 2009 for treatment of anorexia, I did a parachute jump, started volunteering and decided to have a baby on my own. Some of these were impulsive – yet heartfelt – attempts to “catch up” on a life that had been passing me by.
This sense of things moving on while you have been trapped in the depths of an eating disorder is probably even more potent in the intensified temporal rhythms of teenage years.
As Mia Polanco (Sophie Wilde), the 16-year-old protagonist of Everything Now, asks as the school bus conversation jostles around her: “Fuck. How can I have missed so much in seven months?”
This article is part of Quarter Life, a series about issues affecting those of us in our twenties and thirties. From the challenges of beginning a career and taking care of our mental health, to the excitement of starting a family, adopting a pet or just making friends as an adult. The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.
You may be interested in:
Everything Now is a thoughtful, sensitive and entertaining journey through Mia’s experience of teenage life following her discharge from the eating disorder inpatient unit she has been confined to for seven months.
The image of eating disorders
White, middle-class girls with anorexia have long since dominated the representation in film and TV. But eating disorders cut across ethnic boundaries.
Although there can never be any simple correlation between popular media representations of eating disorders and reality, they play a role in shaping wider understandings of eating problems. This includes who might be affected by them. As a result, this under-representation contributes to a culture in which people from minority ethnic backgrounds are under-diagnosed and less likely to access treatment.
Everything Now should be praised for recognising that it’s not just white, middle-class girls who experience eating disorders.
Also, a significant part of the early plot focuses on Mia’s crush on a female student. Historically, clumsy assumptions have supposed that LGBTQ+ girls and women are somehow more “protected” from eating issues than their heterosexual counterparts. This has long since been challenged. Research has shown that sexual minorities may be more at risk due to the complex relationships between oppression, gender identity and sexuality.
Everything Now is one of the first TV shows about eating disorders that did not make me cringe. It is sensitive, carefully researched and it resonated.
The show does a good job of exploring the complexities of recovery – a long and uncertain process that is rarely depicted, perhaps because it is seen as less arresting than the descent into the illness.
Switching between flashbacks of her time in the clinic and her present life at school and home, Mia’s voiceover communicates her struggles and anxieties. It also shows how difficult it is to navigate other people’s perceptions of recovery. Her grandmother, for example, bakes her a coconut sponge to welcome her home, to which Mia internally exclaims: “You’ve got to be fucking kidding me.”
Her grandma then pinches her cheek and says: “You look so wonderful, so healthy.” The implied link between flesh and healthiness can make such comments a minefield for people in recovery.
Mia aims to throw herself back into adolescence, but the series poignantly explores her new status as an insider and outsider – how she is irrevocably changed by her eating disorder.
As the camera pans over the nibbles and drinks at a party she asks: “How can they just eat and drink? How am I 16 and I can’t just do that?” This captures the way spontaneity with food and drink becomes utterly unimaginable, not only during the throes of an eating disorder but during the pressures, regimens and routines of a recovery meal plan.
The voiceover is particularly good at showcasing the disjuncture between Mia’s eagerness and how her eating disorder pulls the brake: “Shots, OK. At least I can track what’s in that. Maybe I can skip something tomorrow. I need to show them I’m better. That I can be normal.” She is both present and not present – one of her peers yet so separate.
Everything Now depicts positive moments of recovery too, in ways that are touching and insightful. As Mia walks to school for the first time, she reflects on “All the everyday beauty I forgot how to see – and all the things I get to rediscover now.”
While the eating disorder has made the everyday strange (the snacks and drinks at the party seem impossible) it has also made the everyday more beautiful. The scene reminded me of a quote from a student in sociologist Paula Saukko’s 2008 book The Anorexic Self: “I used to be able to see the sky, but now I only think about food.”
Everything Now is an original, heartwarming and insightful story of learning to see the sky again.
Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Su Holmes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.link treatment recovery
Surviving and Thriving in an Ugly Stock Market
Surviving and Thriving in an Ugly Stock Market
After a wonderful 2021 for stock investors, the last two years have been rough, to say the…
After a wonderful 2021 for stock investors, the last two years have been rough, to say the least. The next sustained bull market seems to remain in the unknown future.
So let’s look at a couple of market strategies that have worked and will do so no matter how the stock market goes…
It is extremely difficult (for most investors, I’d say it is impossible) to time the market and generate above-average returns from capital gains. I recommend strategies that provide consistent returns.
My Dividend Hunter service focuses on investing in high-yield securities. It has been my best-performing strategy over the last year. Many investors get high-yield investing wrong and stay too focused on share prices. The focus of high-yield investing should be on the cash income stream. Yield means dividends, which are cash returns that don’t go away when share prices go down.
The goal of high-yield investing is to build a stable and growing income stream. I advise my Dividend Hunter subscribers to track their portfolio income quarter after quarter. As long as the income increases, they are fine, and it doesn’t matter what happens to share prices.
Over the long term, a high-yield strategy naturally leads to buying during market downturns. When share prices drop, yields increase, making shares more attractive for income-focused investors. If you make regular monthly contributions, you will buy more shares when the market is down and fewer at market highs. The result will be a lower average share cost and a higher yield on cost.
Starwood Property Trust (STWD) is a long-term Dividend Hunter recommendation. I started my solo 401k in late 2017 and bought my first shares of STWD in January 2018. The first purchase cost $21.18 per share. Over the last six years, I have added STWD shares at prices ranging from $10.96 (at the bottom of the pandemic-triggered crash) to $24.38. My average cost is $17.45 per share, giving me a yield on cost of 11%.
For my Monthly Dividend Multiplier service, I use a dividend growth strategy. You can build wealth by investing in stocks that grow their dividends. You will likely get frustrated with the process before you reach your wealth target.
History shows that the compound annual total returns from a dividend growth stock will end up very close to the average dividend growth rate plus the average dividend yield. For the famous Dividend Aristocrats, this math puts annual returns in the single digits. The realized returns tend to get lost in the short-term market swings, but the math works as you look at five-year and longer time frames.
For the Monthly Dividend Multiplier portfolio, I search out dividend growth stocks where the yield plus dividend growth math gives numbers in the mid-teens. That level of compounding returns will double your money about every five years.
I’ve ensured that the portfolio is diversified across as many sectors as possible that meet my dividend criteria. I track results quarterly and am always surprised by the short-term gains and losses among individual stocks and market sectors. For example, for the third quarter, the Monthly Dividend Multiplier individual returns ranged from gains of over 30% to a loss of more than 30%.
To take advantage of the intermediate swings, I have set weightings for the portfolio stocks, and we rebalance every quarter.
NextEra Energy Partners (NEP) was the big loser for the third quarter. The company reduced its dividend growth guidance from 12% to 15% per year to 5% to 8% through 2026. The NEP share price dropped by 20% in one day and is down double that year to date. But… after the drop, NEP now yields 9%. Add that to 5% dividend growth, and you have potentially mid-teens total annual returns in the future.
Our end-of-Q3 rebalance allowed my subscribers to average down their cost basis on NEP to benefit from future dividend growth.
For years, I’ve stressed investing in dividend stocks for income. However, I’ve recently stumbled on a strategy that could generate up to triple digit winners from dividend stocks. This is brand new and you can see the strategy here.
Ripple’s XRP price jumps 5% fuelled by Singapore licensing acquisition amidst crypto market downturn
Ripple’s XRP emerged as one of the rare gainers during a subdued 24 hours in the cryptocurrency market that saw Bitcoin (BTC) and other top digital assets…
Data from CryptoSlate reveals that XRP surged by approximately 5%, reaching $0.53018 as of press time. This uptick follows Ripple’s significant victories during the reporting period as it secured licensing in Singapore and Judge Analisa Torres rejected the U.S. Securities and Exchange Commission’s (SEC) plea for an interlocutory appeal.
Ripple’s Singapore licensing
Earlier today, Ripple said its subsidiary, Ripple Markets APAC Pte Ltd, secured a “full” Major Payments Institution (MPI) license from the Monetary Authority of Singapore (MAS) to provide digital payment token services in the country. The crypto payment country received an in-principle approval from the regulator in June.
The MPI license enables businesses to operate free from daily and monthly transaction limits. To qualify, the business must possess a Singaporean-registered company or branch, maintain a permanent business address for record-keeping, have a minimum capital of $250,000, and appoint at least one director with Singaporean citizenship or residency.
Ripple CEO Brad Garlinghouse described Singapore as a “progressive jurisdiction” that has ” developed into one of the leading fintech and digital asset hubs striking a balance between innovation, consumer protection, and responsible growth.”
Besides that, Judge Torres’s decision provides a closing chapter to the legal tussle between the company and the SEC for this year, with both parties scheduled for trial by April 23, 2024.
Selling pressure on the horizon
Despite this recent surge, XRP still confronts substantial selling pressure due to Ripple recently releasing one billion tokens from its escrow system.
While the crypto payment firm immediately relocked 800 million XRP, the company still holds 200 million tokens that could add more than $100 million in selling pressure to the market, potentially altering the current upward momentum of the asset.
The post Ripple’s XRP price jumps 5% fuelled by Singapore licensing acquisition amidst crypto market downturn appeared first on CryptoSlate.cryptocurrency bitcoin crypto btc xrp crypto
Eli Lilly to buy radiopharma company Point Biopharma for $1.4B as PhIII readout looms
Bitcoin, Solana products lead first crypto investment inflow since mid-August
The RBA’s battle with inflation: Examining the latest data points
3 Key Relationships to Help Assess Market Direction
Major Asset Classes | September 2023 | Performance Review
New tool reveals how drugs affect men, women differently — and will make for safer medications
One-third of all CFTC crypto enforcement actions took place this year — Chairman Behnam
ICE (Black Knight) Mortgage Monitor: “Home Prices Set Yet Another Record in August”
Book describes Sam Bankman-Fried with little attention span or respect for appointments
Buy Love, Sell Fear
Uncategorized23 hours ago
Eli Lilly to buy radiopharma company Point Biopharma for $1.4B as PhIII readout looms
International24 hours ago
Swiss franc slips as inflation falls
Uncategorized13 hours ago
Cardano stablecoin project gambled away investors’ money before rug: Report
International16 hours ago
Computer model predicts who needs lung cancer screening
International19 hours ago
Airlines are being hit by anti-greenwashing litigation – here’s what makes them perfect targets
International11 hours ago
New robot could help diagnose breast cancer early
Government21 hours ago
Nationwide test of Wireless Emergency Alert system could test people’s patience – or help rebuild public trust in the system
Uncategorized8 hours ago
SEC asks judge to reject Coinbase’s motion to dismiss lawsuit